Roche's Genentech Reports Phase Ib Results For Its Dual GLP-1/GIP Receptor Agonist CT-388 In People With Obesity
Portfolio Pulse from Benzinga Newsdesk
Roche's Genentech reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity, showing significant weight loss and glycemia normalization with no new safety concerns.
May 16, 2024 | 6:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roche's Genentech reports positive Phase Ib results for CT-388, showing significant weight loss and glycemia normalization in obesity treatment with no new safety concerns.
The positive Phase Ib results for CT-388, including significant weight loss and glycemia normalization, are likely to boost investor confidence in Roche's pipeline and future revenue potential. The absence of new safety concerns further strengthens the outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100